"The time between onset of ruxolitinib administration and improvement of health is so short that it is reasonable to assume that the drug ruxolitinib contributed to the favorable clinical course," Neubauer explains. Based on the success of the treatment, the German Federal Institute for Drugs and Medical Devices has approved a clinical trial that will test the effect of the administration of ruxolitinib in additional COVID-19 patients.
MedicalXpress
No comments:
Post a Comment